174 related articles for article (PubMed ID: 19224410)
1. Tiagabine augmentation to fluvoxamine-risperidone combination in the treatment of obsessive-compulsive disorder.
Oulis P; Masdrakis VG; Karapoulios E; Karakatsanis NA; Kouzoupis AV; Konstantakopoulos G; Soldatos CR
World J Biol Psychiatry; 2009; 10(4 Pt 3):953-5. PubMed ID: 19224410
[TBL] [Abstract][Full Text] [Related]
2. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
McDougle CJ; Fleischmann RL; Epperson CN; Wasylink S; Leckman JF; Price LH
J Clin Psychiatry; 1995 Nov; 56(11):526-8. PubMed ID: 7592506
[TBL] [Abstract][Full Text] [Related]
3. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels.
Yoshimura R; Kaneko S; Shinkai K; Nakamura J
Psychiatry Clin Neurosci; 2006 Jun; 60(3):389-93. PubMed ID: 16732759
[TBL] [Abstract][Full Text] [Related]
5. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
6. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
Dwivedi S; Pavuluri M; Heidenreich J; Wright T
J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
[No Abstract] [Full Text] [Related]
7. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
Sun TF; Lin PY; Wu CK
Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
[TBL] [Abstract][Full Text] [Related]
8. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
[TBL] [Abstract][Full Text] [Related]
9. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
11. Obsessive-compulsive disorder with non-24-hour sleep-wake syndrome.
Morinobu S; Yamashita H; Yamawaki S; Tanaka K; Ohkawa M
J Clin Psychiatry; 2002 Sep; 63(9):838-40. PubMed ID: 12363127
[No Abstract] [Full Text] [Related]
12. Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination.
Pratheesh PJ; Praharaj SK; Srivastava A
Psychopharmacol Bull; 2011; 44(1):70-3. PubMed ID: 22506441
[TBL] [Abstract][Full Text] [Related]
13. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
[TBL] [Abstract][Full Text] [Related]
14. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Saxena S; Wang D; Bystritsky A; Baxter LR
J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
[TBL] [Abstract][Full Text] [Related]
15. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
Stein DJ; Bouwer C; Hawkridge S; Emsley RA
J Clin Psychiatry; 1997 Mar; 58(3):119-22. PubMed ID: 9108814
[TBL] [Abstract][Full Text] [Related]
16. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.
Hegde A; Kalyani BG; Arumugham SS; Narayanaswamy JC; Math SB; Reddy YC
J Clin Psychopharmacol; 2016 Aug; 36(4):381-4. PubMed ID: 27219093
[TBL] [Abstract][Full Text] [Related]
18. Comparing the Effects of a Herbal Drug based on
Noras MR; Soltanifar A; Salari R; Jarahi L; Abrishami MH
Curr Drug Discov Technol; 2022; 19(5):e240622206368. PubMed ID: 35748547
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Ringold AL; Elliott MA
J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
[TBL] [Abstract][Full Text] [Related]
20. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.
Pfanner C; Marazziti D; Dell'Osso L; Presta S; Gemignani A; Milanfranchi A; Cassano GB
Int Clin Psychopharmacol; 2000 Sep; 15(5):297-301. PubMed ID: 10993132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]